Taro Pharmaceutical Industries Stock News

Taro (TARO) delivered earnings and revenue surprises of -56.47% and 4.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the c

Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company's strong earnings power and clean balance sheet.

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Full Year Results on May 27, 2022

Posted by Equitymaster Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note. Benchmark indices added to yesterday''s gains following a clawback in European markets and US futures as smart investors saw value in the current market valuations. The Sensex reclaimed 54,600 levels while the Nifty clawed back to 16,300 levels led by media, realty, and auto stocks. The sharp rally comes on hopes of de-escalation of the Russia-Ukraine conflict after the Ukrainian President Zelenskyy indicated that the country was no longer interest in NATO membership, the main reason behind the war. At the closing bell, the BSE Sensex stood higher by 1,223 points (up 2.3%). Meanwhile, the NSE Nifty closed higher by 332 points (up 2.1%). Asian Paints and Reliance Industries were among the top gainers today . Shree Cement and ONGC, on the other hand, were among the top losers today . The SGX Nifty was trading at 16,350, up by 408 points, at the time of writing.

The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD) Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 U/g/0.1 per cent, of Taro Pharmaceuticals The post Aleor Dermaceuticals receives US FDA final approval for Nystatin and Triamcinolone Acetonide Ointment appeared first on Express Pharma .

Taro Pharmaceutical Industries (TARO) will acquire Alchemee from Galderma.The deal includes Alchemees business as well as its flagship acne care brand Proactiv.

Taro Pharmaceutical Industries (TARO) shares closed today at 1.5% above its 52 week low of $43.29, giving the company a market cap of $1B. The stock is currently down 11.7% year-to-date, down 41.3% over the past 12 months, and down 52.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Trading volume this week was 17.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 26640.3% The company's stock price performance over the past 12 months lags the peer average by -431.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (NYSE:TARO) is scheduled to announce Q3 earnings results on Thursday, January 27th, after market close.The consensus EPS Estimate is $0.91 (+37.9% Y/Y) and the…

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Third Quarter Results on January 27, 2022

Taro (TARO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Taro Pharmaceutical Industries (TARO) shares closed today at 1.4% above its 52 week low of $45.00, giving the company a market cap of $1B. The stock is currently down 9.0% year-to-date, down 37.9% over the past 12 months, and down 51.5% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 15.0% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -8230.7% The company's stock price performance over the past 12 months lags the peer average by -389.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Taro Pharmaceutical Industries (TARO) shares closed today at 1.7% above its 52 week low of $46.81, giving the company a market cap of $1B. The stock is currently down 31.7% year-to-date, down 30.3% over the past 12 months, and down 45.4% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 79.5% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -326.5% The company's stock price performance over the past 12 months lags the peer average by -308.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Morgan Stanley boosted its holdings in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 226.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,013 shares of the companys stock after buying an additional 33,979 shares during the quarter. Morgan Stanley owned approximately 0.13% of Taro [] The post Morgan Stanley Boosts Stock Holdings in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) appeared first on ETF Daily News .